CONSTELLATION TECHNOLOGIES LIMITED — Capital/Financing Update 2007

Dec 30, 2007

==> picture [96 x 77] intentionally omitted <==

Company Announcement

31 December 2007

AGENIX RECEIVES FINAL PAYMENT OF $1.0 MILLION FROM PREVIOUSLY ANNOUNCED ANIMAL HEALTH BUSINESS DEAL

On 7 April 2006, Agenix announced that IDEXX Laboratories, Inc of the United States would pay $10 million in cash in consideration for the assignment of the patents and other intangible assets of its AGEN Animal Health business and the granting to IDEXX of an exclusive distributorship for AGEN’s animal health diagnostic products.

The consideration was payable in parts, with $6.7 million being paid at settlement on 24 April 2006. The balance of $3.3 million was to be paid progressively as operational transfer milestones were completed.

To date, $2.3 million had been progressively received.

Agenix has today announced that the remaining $1.0 million has now been received, resulting from completion of final operational business transfer milestones.

END

For more information, please contact:

Mr Ravi Govindan Chairman Agenix Limited Phone: + 65 9878 1233

Agenix Limited [ASX: AGX, OTC (NASDAQ): AGXLY ] is a biopharmaceutical company based in Brisbane, Australia. Through its wholly owned subsidiaries, Agen Biomedical and Agenix Biopharmaceutical (Shanghai), the company has a strategic goal of building and developing a pipeline of therapeutic and imaging products.

Agenix Biopharmaceutical (Shanghai) owns the businesses of two associated Chinese life sciences companies. One, Shanghai Rui Guang Bio-Pharma Development Co., Ltd, is a biopharmaceutical company which has a pipeline of anti-viral drugs in development. Its lead product candidate, a hepatitis B virus drug, has successfully completed Phase III clinical trials in China and received China State Food and Drug Administration new drug approval on 30 September 2007. Sales of You He Ding in China are estimated to grow to in excess of RMB320 million per annum. The company has a deep pipeline of potential anti-viral drugs in development. The second, Shanghai Yi Sheng Yuan Pharmaceutical Co., Ltd, has a GMP certified manufacturing facility which has the capacity to produce 150 million tablets per annum (based on a 5-day working week at 8 hours per day).

Agen Biomedical’s lead candidate is its high-technology blood clot-imaging agent, ThromboView[®] ,which has been undergoing human clinical trials in the United States, Canada and Australia. ThromboView[®] uses radio-labelled antibodies to locate blood clots in the body, and could revolutionise the global clot diagnostic imaging market. Agen reported successful results of a Phase II deep vein thrombosis trial in February 2007. A Phase II pulmonary embolism clinical trial of 50 evaluable patients commenced in the United States and Canada in September 2007. Patient recruitment is scheduled for completion in the second quarter of the 2008 calendar year. ThromboView[®] has now been administered to over 160 patients with no serious adverse events attributable to it. Agen estimates that successful commercialization of ThromboView[®] are likely to result in peak end user sales of in excess of US550 million per annum. ThromboView[®] is being developed with the assistance of the Australian Federal Government through its START scheme. ThromboView[®] is a registered trademark of Agen Biomedical Ltd.

www.agenix.com